Literature DB >> 26323066

Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin.

Michael Zeisberg1, Elisabeth M Zeisberg2.   

Abstract

Among gliptins, linagliptin is unique, because decreased glomerular filtration rate does not require dose reduction. Linagliptin was originally developed to lower blood glucose by inhibiting dipeptidyl peptidase-4 (DPP-4). However, DPP-4 has numerous additional substrates, and thus gliptins possess a vast range of additional off-target effects. Shi et al. report that linagliptin directly targets interaction of DPP-4 with integrin β1, preventing endothelial-mesenchymal transition and ultimately renal fibrosis, providing additional rationale for use of linagliptin in diabetic nephropathy.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26323066     DOI： 10.1038/ki.2015.175

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


  9 in total

1.  Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition.

Authors:  Sen Shi; Swayam Prakash Srivastava; Megumi Kanasaki; Jianhua He; Munehiro Kitada; Takako Nagai; Kyoko Nitta; Susumu Takagi; Keizo Kanasaki; Daisuke Koya
Journal:  Kidney Int       Date:  2015-04-01       Impact factor: 10.612

Review 2.  Diabetes treatment in patients with renal disease: Is the landscape clear enough?

Authors:  Ioannis Ioannidis
Journal:  World J Diabetes       Date:  2014-10-15

3.  Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition.

Authors:  Elisabeth M Zeisberg; Scott E Potenta; Hikaru Sugimoto; Michael Zeisberg; Raghu Kalluri
Journal:  J Am Soc Nephrol       Date:  2008-11-05       Impact factor: 10.121

4.  Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen.

Authors:  Keizo Kanasaki; Sen Shi; Megumi Kanasaki; Jianhua He; Takako Nagai; Yuka Nakamura; Yasuhito Ishigaki; Munehiro Kitada; Swayam Prakash Srivastava; Daisuke Koya
Journal:  Diabetes       Date:  2014-02-26       Impact factor: 9.461

5.  Endothelial-to-mesenchymal transition contributes to cardiac fibrosis.

Authors:  Elisabeth M Zeisberg; Oleg Tarnavski; Michael Zeisberg; Adam L Dorfman; Julie R McMullen; Erika Gustafsson; Anil Chandraker; Xueli Yuan; William T Pu; Anita B Roberts; Eric G Neilson; Mohamed H Sayegh; Seigo Izumo; Raghu Kalluri
Journal:  Nat Med       Date:  2007-07-29       Impact factor: 53.440

Review 6.  The potential for renoprotection with incretin-based drugs.

Authors:  Tetsuhiro Tanaka; Yoshiki Higashijima; Takehiko Wada; Masaomi Nangaku
Journal:  Kidney Int       Date:  2014-07-09       Impact factor: 10.612

7.  (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.

Authors:  Leo Thomas; Matthias Eckhardt; Elke Langkopf; Moh Tadayyon; Frank Himmelsbach; Michael Mark
Journal:  J Pharmacol Exp Ther       Date:  2008-01-25       Impact factor: 4.030

8.  The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?

Authors:  Federica Genovese; Alba A Manresa; Diana Julie Leeming; Morten Asser Karsdal; Peter Boor
Journal:  Fibrogenesis Tissue Repair       Date:  2014-03-28

9.  Diabetic angiopathy and angiogenic defects.

Authors:  Ling Xu; Keizo Kanasaki; Munehiro Kitada; Daisuke Koya
Journal:  Fibrogenesis Tissue Repair       Date:  2012-08-01
  9 in total
  5 in total

Review 1.  Renal Effects of Incretin-Based Diabetes Therapies: Pre-clinical Predictions and Clinical Trial Outcomes.

Authors:  Scott C Thomson; Volker Vallon
Journal:  Curr Diab Rep       Date:  2018-04-13       Impact factor: 4.810

2.  Linagliptin prevents atrial electrical and structural remodeling in a canine model of atrial fibrillation.

Authors:  Tazuru Igarashi; Shinichi Niwano; Hiroe Niwano; Tomoharu Yoshizawa; Hironori Nakamura; Hidehira Fukaya; Tamami Fujiishi; Naruya Ishizue; Akira Satoh; Jun Kishihara; Masami Murakami; Junya Ako
Journal:  Heart Vessels       Date:  2018-05-02       Impact factor: 2.037

Review 3.  Dipeptidyl peptidase-4 and kidney fibrosis in diabetes.

Authors:  Sen Shi; Daisuke Koya; Keizo Kanasaki
Journal:  Fibrogenesis Tissue Repair       Date:  2016-02-13

Review 4.  The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.

Authors:  Keizo Kanasaki
Journal:  Clin Sci (Lond)       Date:  2018-02-28       Impact factor: 6.124

5.  Dipeptidyl peptidase 4 promotes peritoneal fibrosis and its inhibitions prevent failure of peritoneal dialysis.

Authors:  Yi-Chen Li; Pei-Hsun Sung; Yao-Hsu Yang; John Y Chiang; Hon-Kan Yip; Chih-Chao Yang
Journal:  Commun Biol       Date:  2021-01-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.